Total Payments
$41,197
2024 Payments
$8,637
Companies
105
Transactions
1,458
Medicare Patients
2,113
Medicare Billing
$558,836
Payment Breakdown by Category
Food & Beverage$30,917 (75.0%)
Consulting$4,512 (11.0%)
Other$3,670 (8.9%)
Education$2,098 (5.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $30,917 | 1,388 | 75.0% |
| Consulting Fee | $4,512 | 7 | 11.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,556 | 6 | 6.2% |
| Education | $2,098 | 45 | 5.1% |
| Long term medical supply or device loan | $1,115 | 12 | 2.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $5,408 | 14 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $3,731 | 140 | $0 (2024) |
| PFIZER INC. | $1,847 | 111 | $0 (2024) |
| Verastem, Inc. | $1,705 | 2 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $1,584 | 74 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,485 | 113 | $0 (2024) |
| Incyte Corporation | $1,438 | 56 | $0 (2024) |
| Janssen Biotech, Inc. | $1,409 | 44 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,363 | 61 | $0 (2024) |
| Celgene Corporation | $1,277 | 55 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,637 | 290 | Novartis Pharmaceuticals Corporation ($1,532) |
| 2023 | $7,200 | 288 | Janssen Biotech, Inc. ($535.88) |
| 2022 | $6,037 | 252 | Incyte Corporation ($402.26) |
| 2021 | $3,458 | 161 | Novartis Pharmaceuticals Corporation ($392.09) |
| 2020 | $2,573 | 43 | Verastem, Inc. ($1,680) |
| 2019 | $3,659 | 174 | Genentech USA, Inc. ($247.37) |
| 2018 | $2,216 | 123 | Novartis Pharmaceuticals Corporation ($356.63) |
| 2017 | $7,418 | 127 | Teva Pharmaceuticals USA, Inc. ($5,408) |
All Payment Transactions
1,458 individual payment records from CMS Open Payments — Page 1 of 59
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $27.42 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $22.11 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: BioOncology | ||||||
| 12/18/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/17/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $30.27 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $33.78 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.84 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Education | In-kind items and services | $74.99 | General |
| Category: ONC | ||||||
| 12/11/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: Rare Disease | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 12/10/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Food and Beverage | In-kind items and services | $26.25 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/06/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $25.50 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $1.12 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: Immunology | ||||||
| 12/02/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $27.53 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $23.13 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $20.30 | General |
| Category: Hematology/Oncology | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $64.65 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $6.14 | General |
| Category: Hematology | ||||||
| 11/21/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/21/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $31.73 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $27.16 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 616 | 3,208 | $375,859 | $145,383 |
| 2022 | 9 | 467 | 2,394 | $392,068 | $139,200 |
| 2021 | 6 | 527 | 1,504 | $413,448 | $172,869 |
| 2020 | 13 | 503 | 1,093 | $260,221 | $101,383 |
Total Patients
2,113
Total Services
8,199
Medicare Billing
$558,836
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 157 | 441 | $169,397 | $61,274 | 36.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 108 | 297 | $73,686 | $29,597 | 40.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 19 | 107 | $32,192 | $12,790 | 39.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 65 | 65 | $23,107 | $11,399 | 49.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 61 | 66 | $23,868 | $9,590 | 40.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 81 | 108 | $20,346 | $7,693 | 37.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 63 | 72 | $17,248 | $6,752 | 39.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 19 | 214 | $13,978 | $5,617 | 40.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 13 | 13 | $1,603 | $505.34 | 31.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 15 | 1,321 | $336.24 | $127.22 | 37.8% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 15 | 504 | $96.80 | $38.12 | 39.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 141 | 471 | $185,542 | $68,264 | 36.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 114 | 341 | $74,880 | $29,013 | 38.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 21 | 113 | $64,663 | $14,109 | 21.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 64 | 64 | $22,674 | $11,199 | 49.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 52 | 58 | $24,685 | $9,600 | 38.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 36 | 46 | $10,410 | $4,419 | 42.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 15 | 93 | $8,950 | $2,493 | 27.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 11 | 840 | $201.10 | $78.84 | 39.2% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2022 | 13 | 368 | $63.68 | $24.30 | 38.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 207 | 888 | $201,292 | $78,301 | 38.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 109 | 347 | $112,616 | $53,538 | 47.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 120 | 129 | $56,708 | $20,758 | 36.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 49 | 49 | $17,150 | $9,279 | 54.1% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 11 | 49 | $16,156 | $6,730 | 41.7% |
About Dr. Eric Cheung, D.O
Dr. Eric Cheung, D.O is a Hematology & Oncology healthcare provider based in Lakewood, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/04/2008. The National Provider Identifier (NPI) number assigned to this provider is 1881872687.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Cheung, D.O has received a total of $41,197 in payments from pharmaceutical and medical device companies, with $8,637 received in 2024. These payments were reported across 1,458 transactions from 105 companies. The most common payment nature is "Food and Beverage" ($30,917).
As a Medicare-enrolled provider, Cheung has provided services to 2,113 Medicare beneficiaries, totaling 8,199 services with total Medicare billing of $558,836. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Lakewood, CA
- Active Since 02/04/2008
- Last Updated 08/19/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1881872687
Products in Payments
- Treanda (Drug) $2,368
- KISQALI (Drug) $1,973
- Copiktra (Drug) $1,705
- KEYTRUDA (Biological) $1,257
- IMBRUVICA (Drug) $1,207
- OPDIVO (Biological) $1,117
- LIBTAYO (Biological) $1,038
- Lenvima (Drug) $1,014
- TREANDA (Drug) $651.56
- JAKAFI (Drug) $648.35
- GILOTRIF (Drug) $598.70
- CALQUENCE (Drug) $523.61
- REBLOZYL (Biological) $490.40
- MONJUVI (Drug) $487.86
- Stivarga (Drug) $457.35
- BRUKINSA (Drug) $424.05
- IBRANCE (Drug) $421.24
- EPKINLY (Drug) $415.44
- PROMACTA (Drug) $380.73
- Nubeqa (Drug) $367.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Lakewood
Dr. Nauman Moazzam, Md, MD
Hematology & Oncology — Payments: $91,446
Hematology & Oncology $91,446
Dr. Ling Ma, Md, MD
Hematology & Oncology — Payments: $29,611
Hematology & Oncology $29,611
Raghu Nandan, M.d, M.D
Hematology & Oncology — Payments: $9,228
Hematology & Oncology $9,228
Stephen Frank, Md, MD
Hematology & Oncology — Payments: $284.78
Hematology & Oncology $284.78
Sultanali Alidina, M.d, M.D
Hematology & Oncology — Payments: $13.71
Hematology & Oncology $13.71
Dr. Joseph Napoli, M.d, M.D
Hematology & Oncology
Hematology & Oncology